Specialty Pharmacy

In this video produced by the National Psoriasis Foundation, experts offer their insights into improving outcomes for psoriatic arthritis patients.

Researchers seek improved biomarkers to distinguish between malignant and benign disease.

Bill Barre, RPh, vice president of business development at MedImpact Healthcare Systems, discusses the questions specialty providers need to address to reach consumers in the changing health care landscape.

Deborah Cmielewski, Esq., vice president and general counsel at Armada Health Care, discusses key issues regarding HI-Tecj/HIPAA legislation for specialty pharmacies.

Cardiovascular risk related to severity of inflammation, but not associated with disease duration.

Leigh Ann Bruhn, director of Avalere Health, discusses how specialty pharmacies can help achieve the goals of accountable care groups.

Patients with psoriasis, psoriatic arthritis, or both conditions felt that their quality of life decreased if they experienced condition symptoms in more parts of their body.

The United States stands to be a key player in the global oncology biosimilars market, which is predicted to generate up to $12 billion in revenue by 2020.

Drug seeks to mitigate challenge of infusion frequency while protecting against bleeding episodes.

Michael Einodshofer, RPh, MBA, senior director of specialty strategy and innovation at Walgreens, discusses the potential impact of specialty medications on overall drug spending.

According to a retrospective study and a registry analysis, statin therapy may reduce the rate of local breast cancer recurrence in certain types of breast cancer.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses emerging trends in the treatment of cancer that specialty pharmacies need to be aware of.

LBH589, when used in combination with bortezomib and dexamethasone, improved progression-free survival among relapsed and refractory patients with multiple myeloma.

A genetic test in development by Micromedic may help identify patients who are likely to develop bisphosphonate-associated osteonecrosis of the jaw.

Shannon Ambrose, senior director of Specialty Solutions at Prime Therapeutics, discusses the factors that negatively impact medication adherence for specialty drugs.

Patients with prostate cancer may benefit from bone mineral density screenings prior to initiation of therapy, researchers concluded.

Global oncology trend report finds that increased use of hospital outpatient facilities shifts cost burden to patients.

Findings presented at 50th Annual Meeting of ASCO show aromatase inhibitor effective for premenopausal women when combined with ovarian function suppression.

Results from 2 large, long-term clinical trials show benefits of extended-duration treatment with tamoxifen, resulting in an update to treatment guidelines.

Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.

Study assesses the safety and tolerability of TH-302 in combination with dexamethasone.

FDA updates guidelines to expedite the development and review of new drugs.

The theme of this year's meeting is "Science and Society" and will highlight the role of clinicians who treat cancer.

Pharmacists can assist patients with rheumatoid arthritis in overcoming challenges to adherence.

Jeremy Schafer, PharmD, MBA, Senior Director of Specialty Solutions and Manufacturer Relations at Prime Therapeutics, discusses new developments in medication adherence for specialty pharmacy.

Taking more than 5 medications was associated with fatigue and memory problems in multiple sclerosis patients, a new study reports.

Program offers choice and flexibility to improve the specialty patient experience and deliver superior health outcomes.

Independent Pharmacy Cooperative teams with Diplomat's retail specialty network.

The 2014 Kantar Media Pharmacy Readership Survey finds Pharmacy Times is the top choice among pharmacists, and the publication rated first in several key demographics.